Magic Mushrooms and intimacy
Psilocybin and Sexual Function — What a 2024 Imperial College Study Found
A first-of-its-kind dataset combining clinical and naturalistic research suggests psilocybin may improve sexual wellbeing — and raises important questions about psilocybin vs antidepressants.
The Study
In 2024, Tommaso Barba and colleagues at Imperial College London’s Centre for Psychedelic Research published a study in Nature Scientific Reports that, for the first time, combined prospective survey data with clinical trial results to examine how psychedelics affect sexual functioning.
The study drew from two sources: a survey of 261 people who completed questionnaires before, four weeks after, and six months after a psychedelic experience — and previously unpublished data from a randomized controlled trial comparing psilocybin with escitalopram (a common SSRI) for depression.
It was not the first paper ever written about psychedelics and sex. But it was the first to combine longitudinal self-report data with controlled clinical data on the topic.
What They Found
Across both datasets, participants reported improvements in several areas of sexual wellbeing after their psychedelic experience. These included pleasure, arousal, satisfaction, communication during sex, attraction to their partner, body image, and sense of emotional connection.
Effects were statistically significant but modest, and based on self-reported questionnaires. Some domains improved more than others, and some effects diminished over time. Still, the overall direction was consistent: participants were more likely to report improvements than declines across all measured areas, with some effects persisting up to six months.
It’s worth emphasizing: these findings describe what happened after the experience — not during it. And because the naturalistic arm had no placebo control, the results show association, not confirmed causation. Expectancy effects and self-selection likely play a role.
Psilocybin vs Antidepressants
The clinical trial data offered a particularly relevant comparison. Patients treated with psilocybin reported positive changes in sexual function. Those treated with escitalopram did not.
This contrast matters in the broader conversation around psilocybin vs antidepressants. Sexual dysfunction is one of the most common side effects of SSRIs, affecting an estimated 40–65% of patients. It’s also one of the leading reasons people stop taking their medication — which can trigger depressive relapse.
However, the trial was not primarily designed to measure sexual outcomes, so this comparison is suggestive rather than definitive. More targeted research is needed.
This is also relevant context for people who microdose mushrooms for anxiety. Anxiety and sexual dysfunction are closely linked, and many people managing anxiety with SSRIs experience sexual side effects as a direct consequence. While the Imperial College study did not examine microdosing — it involved full-dose psychedelic experiences — the underlying question is worth following: can psilocybin address anxiety-related conditions without the sexual trade-offs of conventional treatment? The data doesn’t answer that yet, but it points in an interesting direction.
Why Might This Happen?
The researchers proposed several hypotheses — and they’re clear these are hypotheses, not conclusions.
Psilocybin activates serotonin 5-HT2A receptors, which are involved in mood, emotional processing, and sexual behavior. It has also been shown to reduce amygdala reactivity to negative stimuli — essentially quieting the fear response — and to increase emotional empathy without impairing cognitive function.
Preclinical research in mice suggests psychedelics may increase oxytocin signaling and reopen critical periods of social reward learning, though this has not been directly demonstrated in humans with psilocybin specifically.
Psychedelic experiences are also consistently associated with lasting increases in mindfulness and presence — qualities that independent research has linked to sexual satisfaction.
Taken together, these mechanisms could help explain improvements in magic mushroom intimacy: less mental noise, more emotional openness, greater capacity for connection. But the causal chain remains hypothetical.
Implications for Relationships
The study measured individual outcomes, not couples dynamics. But the findings — improved communication, empathy, attraction, and connection — are clearly relevant to psilocybin relationships and partnerships.
The researchers themselves noted that the results open possibilities for couples therapy applications. A 2025 paper in Contemporary Family Therapy explored this direction, examining the potential of psilocybin and MDMA in relational therapeutic settings. This line of research is early but promising.
What This Doesn’t Mean
This is not about performance. The study measured subjective experience and emotional connection, not physical metrics.
Causation is not established. The naturalistic data shows association. Controlled trials are needed to confirm whether psilocybin directly causes these improvements.
The research is preliminary. This was one study with moderate sample sizes. It opens a door — it doesn’t close a debate.
Not everyone responds the same way. Individual experiences vary based on dose, mindset, setting, and personal history.
The Bigger Picture
The improvements in sexual wellbeing reported in this study are not a standalone finding. They appear to be downstream effects of the same processes that make psilocybin therapeutically interesting for depression, anxiety, and addiction: enhanced emotional processing, reduced rigidity, and deeper human connection.
Whether the context is magic mushroom intimacy, the comparison of psilocybin vs antidepressants, or the growing interest among people who microdose mushrooms for anxiety — the through-line is the same.
Science is catching up to what many have already felt: that presence changes everything.
Sources:
- Barba, T. et al. (2024). “Psychedelics and sexual functioning: a mixed-methods study.” Scientific Reports. DOI: 10.1038/s41598-023-49817-4
- Nardou, R. et al. (2023). “Psychedelics reopen the social reward learning critical period.” Nature. DOI: 10.1038/s41586-023-06204-3
- Pokorny, T. et al. (2017). “Effect of Psilocybin on Empathy and Moral Decision-Making.” International Journal of Neuropsychopharmacology. DOI: 10.1093/ijnp/pyx047
- Barrett, F.S. et al. (2020). “Emotions and brain function are altered up to one month after a single high dose of psilocybin.” Scientific Reports. DOI: 10.1038/s41598-020-59282-y
- Kruger, D. et al. (2025). “Psychedelics and sex: perceived impacts on sexuality and intimacy.” Journal of Sex Research.